GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd Board Approves Un-audited Financial Results

BOARD ● No Immediate Change LOW RISK
📅 Filed on BSE: 10 Nov 2026, 04:53 PM IST  ·  BSE ID: 6e034b73-0dc1-494f-8ea2-61ccfdc13ced
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board met to approve its latest financial statements for the recent quarter and half-year period.
🤖 AI Summary
  • Board of Directors approved un-audited financial results for Q2 and H1 FY27.
  • Limited Review Report for the quarter ended September 30, 2026, was approved.
  • Meeting held on November 10, 2026, at the company's corporate office.
  • Financial results cover the period ending September 30, 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Period of Results
Quarter and half year ended 30.09.2026
🏢 How This Affects the Company
💰
Financial Impact
The approval and disclosure of financial results provide an update on the company's financial performance for the specified periods.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders. Investors can review the disclosed financial results.
👤
Who Is Affected
All shareholders are affected as the financial performance update is now publicly available.
🔍
Management Signal
Management is adhering to regulatory requirements for financial reporting and transparency.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Detailed Q2 FY27 financial report release
Analysis of the limited review report findings
Subsequent board meetings and strategic disclosures
LOW RISK Routine board meeting outcome to approve standard financial reporting.
💡 Investor Takeaway
Oxygenta Pharmaceutical Ltd's Board approved un-audited financial results for Q2 and H1 FY27, ending September 30, 2026. A limited review report for the quarter was also cleared.
❓ Frequently Asked Questions
What did the Oxygenta Pharmaceutical Ltd Board of Directors decide on November 10, 2026?
The Board approved the un-audited financial results for the quarter and half-year ended September 30, 2026, and the Limited Review Report for the quarter.
What financial period do the approved results cover for Oxygenta Pharmaceutical Ltd?
The approved results cover the quarter and the half-year period that ended on September 30, 2026.
When was the Oxygenta Pharmaceutical Ltd board meeting held?
The board meeting was held on Tuesday, November 10, 2026, starting at 12:30 p.m. and concluding at 4:00 p.m.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.